Sponsored by:

Nuclear Medicine

Telix inks deal to acquire ITM for $1.65B
By Erik L. Ridley
The deal would create a combined company with significant radioisotope manufacturing, distribution, and radiopharmaceutical development capabilities.
September 21, 2026
Isotopes1
Curium gets FDA approval for Lu-177 injection for GEP-NETs
By AuntMinnie.com staff writers
The radioligand therapy delivers targeted radiation to GEP-NETs by binding to somatostatin receptors expressed on these tumors.
September 15, 2026
Approved Stamp 400
Ionetix begins shipping At-211 in North America
By AuntMinnie.com staff writers
Alpha emitters like At-211 deliver high-energy radiation over a very short range.
September 2, 2026
Nuclear Medicine
IU Health launches theranostics center
By AuntMinnie.com staff writers
The center is supported by a $40 million commitment.
August 19, 2026
Nuclearmedicine
Radnostix reports revenue decline in Q2
By AuntMinnie.com staff writers
The company attributed the revenue dip to two voluntary product recalls and the Cobalt-60 hot-cell shutdown.
August 13, 2026
Research Money 400
ITM receives Complete Response Letter for ITM-11
By AuntMinnie.com staff writers
The FDA stated that it's unable to approve the NDA in its present form.
August 10, 2026
Nuclear Medicine
Plus Therapeutics rebrands as Cerenome
By AuntMinnie.com staff writers
The move reflects the company's evolution from a therapeutics-focused organization into an integrated central nervous system (CNS) oncology company.
August 3, 2026
Cerenome
Novartis secures expanded approval for Pluvicto
By AuntMinnie.com staff writers
Pluvicto can now be used as therapy in patients with PSMA-positive metastatic hormone-sensitive prostate cancer, in combination with an androgen receptor pathway inhibitor.
July 31, 2026
Prostate Imaging
SNMMI issues analysis of 2027 HOPPS proposed rule
By AuntMinnie.com staff writers
The proposed rule includes several positive code-level changes for nuclear medicine providers.
July 29, 2026
Snmmi
ITM launches new oncology therapeutics division
By AuntMinnie.com staff writers
Lumara Bio will focus resources toward commercial readiness for ITM's lead drug candidate, lutetium-177 (Lu-177) edotreotide (ITM-11).
July 27, 2026
Lumara
Lutetium-177 PSMA-617 shows promise in earlier-stage prostate cancer
By Will Morton
Across 14 studies, PSA50 response rates (the number of patients with at least a 50% drop in PSA) ranged from 44% to 100%.
July 21, 2026
Prostate Imaging
GE HealthCare introduces MIM Anyware remote access platform
By AuntMinnie.com staff writers
The platform allows authorized users to access MIM software applications from any location without local installation.
July 21, 2026
Ge Health Care Logo New March 2023
Page 1 of 445
Next Page